The fine and specialty chemicals business: how it really works: Industry structure, cycles and the shift east

5.1 A fragmented industry where size brings little advantage

Pollak counts several thousand fine chemical enterprises; the CPhI trade fair catalogue alone lists about 1,400. The top 20 hold only about 20% of the market, against more than 50% for the top 20 drug companies. He groups them in three tiers of roughly $10 billion of sales each: about ten big players above $250 million, with several sites and over 500 m3 of reactors, mostly divisions of large groups; about 50 medium firms of $100-250 million, often private 'pure players'; and over 500 small firms under $100 million, mostly in Asia and often specialised in one niche.

Few were founded as fine chemical firms. Many grew from fertilisers or commodities (BASF, Lonza), coal (DSM), noble metals (Evonik) or explosives (SNPE), or were spun out of drug makers (Siegfried). Some idle dye-intermediate plants, descendants of the previous module's industry, were upgraded for drug intermediates.

Size does not pay because most fine chemicals are made in tens of tonnes in the same 4-6 m3 vessels everywhere, so cost per m3-hour hardly changes with company size. Big firms instead suffer quarterly stock-market pressure, slow multi-site decisions and portfolios patched together by acquisition. Customers prefer midsized suppliers, where they can reach the decision maker.

The merger record bears this out. Around 2000, specialty chemical groups such as Clariant, Rhodia, Degussa and Dow bought fine chemical firms at high multiples. Clariant paid 28 times earnings, about $1.7 billion, for BTP in 2000, wrote almost all of it off and later sold it. By 2005 price-earnings ratios had fallen from above 20 to below 10, private equity bought cheaply, and big pharma began selling plants: Pfizer cut from 100 to 43 by 2008.

• Pollak (2011) · pdf pp. 30-37, 43-47, 121, 225-226

5.2 Because costs are fixed, capacity utilisation swings profits by a factor of two

Pollak describes three booms in the industry's roughly 30-year life. The first, in the late 1970s, came when the ulcer drugs Tagamet and Zantac outran their owners' plants. The second, in the late 1990s, came with high-dose anti-AIDS drugs and COX-2 painkillers, and fed the acquisition spree. A minor third came from government stockpiling of flu drugs; Roche used more than 15 outside contractors in 9 countries for Tamiflu. Busts followed after 2000, in 2004-05 and in 2008-09, the last driven mainly by drug makers cutting inventories and cancelling orders.

Underlying demand from innovators thinned: FDA approvals of new small-molecule drugs fell from 51 in 1997 to 15 in 2005, while new capacity, much of it in Asia, kept arriving.

Because costs are fixed, profits swing. Over 2000-2009 representative Western firms earned EBITDA (earnings before interest, tax, depreciation and amortisation) of about 15% of sales and EBIT of about 7-8%; about 20% and 10-13% in booms, 10% and 5% in busts. Pollak reads the factor of two as sensitivity to capacity utilisation. To avoid closures, Western firms accepted prices covering only variable cost. Their costs are mostly in euros, their sales in dollars. On average they earned below their cost of capital.

Customer structure adds risk. Fourteen drug companies account for over half of demand. They keep preferred-supplier lists, rarely pay for the spare capacity they expect, take the gains from process improvements and may bring a successful product back in-house. In a benchmark of 45 Western producers, more than half earned below the cost of capital in 2002; in 2009 almost half made under 5% on sales.

• Pollak (2011) · pdf pp. 34, 105-108, 121-125

5.3 India and China win on cost and generics; the West keeps the exclusive end

Pollak calls globalisation the trend with the largest impact on fine chemicals after the drug industry's own troubles. An operator costs about $50,000-60,000 a year in the US and Western Europe and $4,000-5,000 in India and China. Productivity is lower in Asia, $65,000-70,000 of output per employee against $250,000-300,000, but the adjusted advantage is still about 2.8 for India and 3.2 for China. In his price structure for a pharmaceutical fine chemical, raw materials take a bigger share in India (45% against 35%, partly because utilities cost more), while capital (6% against 13%) and overheads (15% against 25%) are much smaller, leaving an EBITDA margin of about 25% against 15%. With 4 m3 reactors an Indian plant runs at a fifth of a Western contractor's cost per m3-hour.

The result shows most in API-for-generics. By 2008 Asia-Pacific held about 55% of the merchant market, while Europe still held 48% of merchant APIs for patented drugs. India had filed 1,485 drug master files, 78% of them after 2000, against 981 for the US, 627 for Italy and 475 for China. Four Indian firms (Dishman, Divi's, Hikal, Jubilant) grew about 25% a year in 2001-2009, against about 6% for four Western peers. A shorthand Pollak quotes: China leads in drug substances, India in drug products.

The West keeps an edge where trust matters: advanced cGMP intermediates for patented drugs. Pollak's caveats on Asian sourcing are total cost of ownership, uneven protection of intellectual property and supply risk; one German drug maker found both its Chinese suppliers relied on a single starting-material plant that authorities shut for pollution. European firms typically keep the final regulated steps and buy nonregulated intermediates in Asia: Saltigo bought nearly 90% of raw materials in Europe in 2004 but only about 50% in 2008, saving over 30%.

• Pollak (2011) · pdf pp. 124-127, 171, 186-189, 204-212, 240
• Cefic (2025) · Sales, Extra-EU27 Exports and Extra-EU27 Imports sheets

5.4 R&D is mostly development, marketing is mostly relationships, and the winners are midsized specialists

Fine chemical R&D is 'small r, big D': designing or adapting laboratory procedures, scaling them up (a factor of 100,000 from a 10 g sample to a 1 tonne batch) and optimising running processes. Spending is about 5-10% of sales, against 2-5% for commodities. Wittcoff's 2000 figures put research at 3.6% of sales for basic industrial chemicals, 4.2% for specialties and 14.5% for life sciences; Cefic's 2024 data put world chemical R&D at EUR 57 billion, about 1.1% of sales. A laboratory chemist judges a route by yield; a plant judges it by kilograms per m3 per hour.

Marketing is specialised too. Pollak separates sales of API-for-generics, a commercial job, from business development for custom manufacturing, which needs a chemist with commercial flair and a five-year horizon. One marketing manager handles $10-15 million of sales, so a $100 million firm needs seven to ten. Three to five 'tier I' key accounts typically bring 75-80% of sales. Promotion rarely exceeds 0.5% of sales; personal contacts and plant visits beat advertising. The CPhI fair grew from 16 exhibitors in 1990 to 1,530 in 2009, over 40% of them Asian.

What makes a company succeed? Pollak's overriding test is a track record of completed projects with major customers, because hardware is similar everywhere while reputation, FDA inspection history and ease of doing business differ. He names three indicators: a presence in Asia; ownership and size, ideally a private or family firm of $100-250 million, big enough for a broad toolbox yet quick; and differentiating technology, such as hazardous-gas chemistry, high-potency actives (a potential $5 billion market by 2015) or biotechnology. One-stop shops and consolidation, he argues, are not the answer.

• Pollak (2011) · pdf pp. 88-92, 122, 162-166, 194-198, 251-255
• Wittcoff (2004), Ch 1 · pdf pp. 67-68
• Cefic (2025) · R&D Spending and Sales sheets

Check your understanding

Why, according to Pollak, do large fine chemical companies not enjoy economies of scale?

Western fine chemical EBITDA margins were about 20% in booms and 10% in busts. What does Pollak see behind this factor of two?

Which segment did Asian producers dominate by 2008, according to Pollak's data?